Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).

Abstract

Oritavancin displayed potent and stable activity (MIC90 range of 0.06 to 0.5 mg/L) over a 10-year period (2010 to 2019) against Gram-positive pathogens that cause bloodstream infections (BSI), including methicillin-resistant Staphylococcus aureus (MRSA) and resistant subsets of Enterococcus spp. Daptomycin and linezolid were also active against methicillin-resistant S. aureus and vancomycin-resistant Enterococcus (VRE). Only oritavancin and linezolid remained active against Enterococcus faecium isolates displaying an elevated daptomycin MIC (i.e., 2 to 4 mg/L). Proportions of methicillin-resistant S. aureus and vancomycin-resistant Enterococcus within the respective S. aureus and enterococcal populations decreased over this period.

• Authors: Cecilia G Carvalhaes, Helio S Sader, Jennifer M Streit, Mariana Castanheira, Rodrigo E Mendes
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 66 Issue 2 Pg. e0166721 (02 15 2022) ISSN: 1098-6596 [Electronic] United States
• PMID: 34807761 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Lipoglycopeptides
• oritavancin

Topics

• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Gram-Positive Bacterial Infections (drug therapy, epidemiology)
• Humans
• Lipoglycopeptides (pharmacology, therapeutic use)
• Methicillin-Resistant Staphylococcus aureus (drug effects)
• Microbial Sensitivity Tests
• Sepsis (drug therapy, microbiology)
• United States (epidemiology)
• Vancomycin-Resistant Enterococci (drug effects)